Travere Therapeutics

TVTX

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$1.9m

Combined value at quarter end

Last quarter

1 bought

0 sold or trimmed

Price at Q2 ’26 end

$56.81

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

0Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Travere Therapeutics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Travere Therapeutics

Polen Capital Management	0.0%$1.9m	$1.9m	New	1 qtr

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Travere Therapeutics
		Bought or sold				Filing
15 Oct 2026	Dube Eric MCHIEF EXECUTIVE OFFICER	▼ Sold	128,065	$52.97	$6.8m	Form 4
15 Oct 2026	Dube Eric MCHIEF EXECUTIVE OFFICER	▼ Sold	78,400	$55.02	$4.3m	Form 4
15 Oct 2026	Dube Eric MCHIEF EXECUTIVE OFFICER	▼ Sold	37,270	$54.20	$2.0m	Form 4
17 Sep 2026	Dube Eric MCHIEF EXECUTIVE OFFICER	▼ Sold	101,691	$64.59	$6.6m	Form 4
17 Sep 2026	Heerma PeterEVP, CHIEF COMMERCIAL OFFICER	▼ Sold	8,282	$65.07	$539k	Form 4
17 Sep 2026	Dube Eric MCHIEF EXECUTIVE OFFICER	▼ Sold	6,802	$64.95	$442k	Form 4
16 Sep 2026	Dube Eric MCHIEF EXECUTIVE OFFICER	▼ Sold	99,716	$63.26	$6.3m	Form 4
16 Sep 2026	Dube Eric MCHIEF EXECUTIVE OFFICER	▼ Sold	96,125	$63.64	$6.1m	Form 4
16 Sep 2026	Heerma PeterEVP, CHIEF COMMERCIAL OFFICER	▼ Sold	93,604	$63.25	$5.9m	Form 4
16 Sep 2026	Heerma PeterEVP, CHIEF COMMERCIAL OFFICER	▼ Sold	79,113	$63.65	$5.0m	Form 4
16 Sep 2026	Rote William E.Chief Research Officer	▼ Sold	65,104	$63.12	$4.1m	Form 4
16 Sep 2026	Rote William E.Chief Research Officer	▼ Sold	47,746	$63.61	$3.0m	Form 4
15 Sep 2026	Heerma PeterEVP, CHIEF COMMERCIAL OFFICER	▼ Sold	71,938	$62.05	$4.5m	Form 4
15 Sep 2026	Rote William E.Chief Research Officer	▼ Sold	63,907	$61.99	$4.0m	Form 4
15 Sep 2026	Dube Eric MCHIEF EXECUTIVE OFFICER	▼ Sold	63,498	$61.99	$3.9m	Form 4
15 Sep 2026	Rote William E.Chief Research Officer	▼ Sold	29,021	$62.66	$1.8m	Form 4
15 Sep 2026	Dube Eric MCHIEF EXECUTIVE OFFICER	▼ Sold	28,796	$62.66	$1.8m	Form 4
15 Sep 2026	Heerma PeterEVP, CHIEF COMMERCIAL OFFICER	▼ Sold	27,421	$62.59	$1.7m	Form 4
15 Sep 2026	Cline Christopher R.CHIEF FINANCIAL OFFICER	▼ Sold	27,473	$62.00	$1.7m	Form 4
15 Sep 2026	Inrig JulaEVP, Head of R&D & CMO	▼ Sold	25,390	$62.02	$1.6m	Form 4

About the company

Sector: Health care · Pharmaceutical Preparations
Incorporated in: California
Financial year ends: 31 December
Shares outstanding: 94m at 30 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

2013

2015

$155m2017

$175m2019

$132m2021

$145m2023

$491m2025

Travere Therapeutics revenue and net income by year
Year	Revenue	Net income
2025	$491m	−$25.5m
2024	$233m	−$322m
2023	$145m	−$111m
2022	$109m	−$278m
2021	$132m	−$180m
2020	$198m	−$169m
2019	$175m	−$146m
2018	$164m	−$103m
2017	$155m	−$59.7m
2016	$134m	−$47.9m
2015	–	$117m
2014	–	−$111m
2013	–	−$34.6m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.